Sanara MedTech Inc. and Biomimetic Innovations Provide Update on OsStic™

Barchart · 2d ago

Poised for U.S. market launch in Q1 2027 following the achievement of recent milestones and OsStic’s granted patent in 2025

FORT WORTH, TX, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, together with Biomimetic Innovations Ltd (“BMI”), today provided an update on progress related to their strategic alliance. In addition, Sanara reaffirmed its plans to introduce OsStic Synthetic Injectable Structural Bio-Adhesive (“OsStic”) to the U.S. commercial market in the first quarter of 2027, following anticipated clearance by the U.S. Food and Drug Administration (“FDA”), to support reduction and provisional fixation treatment of the more than 100,000(1) peri-articular fractures occurring annually nationwide.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.